<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817583</url>
  </required_header>
  <id_info>
    <org_study_id>NPC20081</org_study_id>
    <secondary_id>NPC20081</secondary_id>
    <secondary_id>NPC20081-1</secondary_id>
    <nct_id>NCT00817583</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)</brief_title>
  <acronym>TPF for NPC</acronym>
  <official_title>Phse II Study of Induction Chemotherapy With TPF Regimen Followed by Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the response rate, tolerance and overall
      survival in patients with stage III, IVa, IVb NPC treated with neoadjuvant chemotherapy (TPF
      regimen) and concurrent chemoradiation.

      Secondary objectives of the study are to evaluate the distant metastases free survival, and
      disease-free survival of patients with stage III,IVa, IVb NPC treated with this regimen.

      The third objective of this study is to evaluate who may benifit from this treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent chemoradiation is the standard treatment for locally advanced NPC. The survival
      benefit gained from adding induction chemotherapy to concurrent chemoradiation has not been
      defined yet. In the present clinical study, we hope to assess the tolerance and survival
      benefits of induction chemotherapy followed by concurrent chemoradiation in patients with
      stage III, IVa and IVb NPC.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>distant metastases free survival , and disease-free survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, cisplatin, fluorouracil</intervention_name>
    <description>neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.
concurrent chemotherapy:cisplatin 40 mg/m2 weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  -Histopathologically proved WHO type II and type III carcinoma of the nasopharynx.

          -  Stage â…¢, IVa and IVb disease

          -  KPS &gt;70

          -  Age between 18-70

          -  Patients should have adequate bone marrow function defined as an absolute peripheral
             granulocyte count (AGC) of &gt; 2000 cells/mm3, platelet count of &gt; 100,000 cells/mm3
             (pre treatment without intervention). Bilirubin &lt; 1.5 mg/dl, AST or ALT&lt;2 x upper
             normal, serum creatinine&lt;1.5mg/dl, creatinine clearance &gt;50ml/min.

          -  the primary tumor or involved lymph node must be more than 2CM in diameter.

          -  No prior radiation treatment to the head and neck or any prior chemotherapy

          -  Patients with no prior malignancy (not include basal cell carcinoma of skin)

        Exclusion Criteria:

          -  Evidence of metastases (below the clavicle or distant) by clinical or radiographic
             examinations.

          -  Prior radiotherapy to the head and neck region for any reason.

          -  Initial surgical treatment excluding diagnostic biopsy of the primary site or neck
             disease.

          -  Patients with previous or simultaneous primaries, excluding basal cell carcinoma or
             squamous cell carcinoma of skin.

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XiaoShen WANG, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ChaoSu HU, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Radiation Oncology, Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ChunYing Shen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HongMei Ying, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ChaoSu HU, M.D.</last_name>
    <phone>86-21-64175590</phone>
    <phone_ext>6517</phone_ext>
    <email>hucsu62@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>XiaoShen WANG, M.D.</last_name>
    <phone>86-21-64175590</phone>
    <phone_ext>6516</phone_ext>
    <email>wangxiaoshen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoshen Wang, M.D.</last_name>
      <phone>86-21-64175590</phone>
      <phone_ext>6516</phone_ext>
      <email>wangxiaoshen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>TingTing Xu, M.D.</last_name>
      <phone>86-21-64175590</phone>
      <phone_ext>6511</phone_ext>
      <email>littlepuppyxtt@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>January 26, 2009</last_update_submitted>
  <last_update_submitted_qc>January 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>cancer hospital, Fudan University</name_title>
    <organization>cancer hospital, Fudan University</organization>
  </responsible_party>
  <keyword>Phase 2 Clinical Trial</keyword>
  <keyword>NPC</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>concurrent chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

